Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-Small Cell Lung Cancer

Next Previous
Trial Profile

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-Small Cell Lung Cancer

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Malignant melanoma
  • Focus Adverse reactions
  • Acronyms PNV21-001

Most Recent Events

  • 21 Mar 2025 Planned number of patients changed from 20 to 25.
  • 23 Jul 2024 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
  • 23 Jul 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top